InsidersTradesSigma
Explore the full directors' dealings record of Cellular Biomedicine Group, Inc., a publicly traded company based in United States. Shares trade on US US, under the authority of SEC (Form 4). Market capitalisation: €1.8bn. The latest transaction was filed on 21 January 2016 (Levée d'options). Among the most active insiders: Chan Andrew K. The full history is free.
Analysts rate Cellular Biomedicine Group, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$57.10.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
4 of 4 declarations
Cellular Biomedicine Group, Inc. is a company focused on developing cell therapies for the treatment of serious diseases. It is listed on NASDAQ under the symbol CBMG.